The Peptic Ulcer Partnering report provides understanding and access to the peptic ulcer partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Irritable Bowel Syndrome Partnering report provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Crohn's Disease Partnering report provides understanding and access to the crohn's disease partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Ulcerative Colitis Partnering report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Inflammatory Bowel Disease Partnering report provides understanding and access to the inflammatory bowel disease partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Gastrointestinal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Salix Pharmaceuticals is a leading specialty pharmaceutical company, listed in the top 50 big biotech list by Current Partnering. Read the full story

Specialty Pharmaceuticals Company Salix Pharmaceuticals is committed to providing treatments for a wide spectrum of gastrointestinal disorders. Read the full story

Salix Pharmaceuticals has announced 3 M&A deals since 2009, with the deals being the acquisition of Santarus, Oceana Therapeutics and the merger between Salix and Cosmo Pharmaceuticals. Read the full story

Nektar Therapeutics stands to get $25 million from AstraZeneca's filing for Naloxegol, as part of previous pharma deals. Read the full story